Histomorphological variations in progressive multifocal leukoencephalopathy correlated with JCV replication in brain

Kenta Takahashi1, Yuko Sato1, Hideki Hasegawa1,2

  • 1Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan.

Insights

Histopathological variability in progressive multifocal leukoencephalopathy (PML) reflects viral activity. Comprehensive evaluation combining histomorphology, PCR, and IHC is crucial for diagnosis and assessing disease progression.

Area of Science:

  • Neuropathology
  • Virology
  • Infectious Diseases

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by JC polyomavirus (JCV).
  • PML histopathology is classically defined by demyelination, enlarged oligodendroglial nuclei, and bizarre astrocytes.
  • The frequency of this triad and its correlation with disease progression and viral load are unclear.

Purpose of the Study:

  • To investigate the histopathological diversity of PML.
  • To correlate histopathological findings with JC polyomavirus (JCV) loads and disease progression.
  • To develop a histological classification system for PML lesions.

Main Methods:

  • Analysis of 117 brain tissues from 91 pathologically confirmed PML patients.
  • Quantitative PCR and immunohistochemistry (IHC) for JCV detection.
  • Development of a histological classification based on the classical triad and macrophage infiltration.

Main Results:

  • PML histopathology is pleomorphic, with not all cases showing the complete classical triad.
  • Quantitative PCR achieved 100% sensitivity for JCV detection; IHC sensitivity ranged from 83.5-87.8%.
  • Viral loads were higher in biopsies than autopsies and decreased over time; classification correlated with viral loads.

Conclusions:

  • Histomorphological variability in PML reflects viral replication activity.
  • Comprehensive pathological evaluation, including histomorphology, PCR, and IHC, is crucial for assessing disease progression.
  • Early brain biopsy from the demyelination border aids definitive diagnosis and guides therapy.